RATIONALE: Chronic antidepressant treatment increases glucocorticoid-mediated negative feedback on the hypothalamic-pituitary-adrenal (HPA) axis, and thus reduces HPA axis activity, in depressed patients and healthy controls. In contrast, acute antidepressant treatment induces an activation of basal HPA axis activity. OBJECTIVES: We examined the effects of 4 days of treatment with the selective serotonin reuptake inhibitor, citalopram, on basal salivary cortisol and on suppression of salivary cortisol by prednisolone. METHODS: We used a single-blind, placebo-controlled, repeated-measure design. Salivary cortisol was measured from 0900 to 1700 hours. In the first phase of the study, basal salivary cortisol secretion was measured on 2 study days, before and after 4 days of treatment with citalopram (orally, 20 mg/day). In the second phase, salivary cortisol secretion after suppression by prednisolone (5 mg, given at 2200 hours the night before) was measured on 2 study days, again before and after 4 days of treatment with citalopram (orally, 20 mg/day). Eight volunteers participated to the study. RESULTS:Citalopram increased basal salivary cortisol in the morning (0900-1100 hours) by approximately 47% (P=0.003). Moreover, citalopram increased suppression by prednisolone in the morning (0900-1100 hours): suppression was approximately 22% before citalopram and 45% after citalopram (P=0.05). CONCLUSIONS:Citalopram increases glucocorticoid-mediated negative feedback on the HPA axis after as little as 4 days of treatment. This effect could be due to an increased function of the corticosteroid receptors. Our findings further support the notion that one of the mechanisms by which antidepressants exert their therapeutic effects is by normalizing HPA axis hyperactivity in depressed patients.
RCT Entities:
RATIONALE: Chronic antidepressant treatment increases glucocorticoid-mediated negative feedback on the hypothalamic-pituitary-adrenal (HPA) axis, and thus reduces HPA axis activity, in depressedpatients and healthy controls. In contrast, acute antidepressant treatment induces an activation of basal HPA axis activity. OBJECTIVES: We examined the effects of 4 days of treatment with the selective serotonin reuptake inhibitor, citalopram, on basal salivary cortisol and on suppression of salivary cortisol by prednisolone. METHODS: We used a single-blind, placebo-controlled, repeated-measure design. Salivary cortisol was measured from 0900 to 1700 hours. In the first phase of the study, basal salivary cortisol secretion was measured on 2 study days, before and after 4 days of treatment with citalopram (orally, 20 mg/day). In the second phase, salivary cortisol secretion after suppression by prednisolone (5 mg, given at 2200 hours the night before) was measured on 2 study days, again before and after 4 days of treatment with citalopram (orally, 20 mg/day). Eight volunteers participated to the study. RESULTS:Citalopram increased basal salivary cortisol in the morning (0900-1100 hours) by approximately 47% (P=0.003). Moreover, citalopram increased suppression by prednisolone in the morning (0900-1100 hours): suppression was approximately 22% before citalopram and 45% after citalopram (P=0.05). CONCLUSIONS:Citalopram increases glucocorticoid-mediated negative feedback on the HPA axis after as little as 4 days of treatment. This effect could be due to an increased function of the corticosteroid receptors. Our findings further support the notion that one of the mechanisms by which antidepressants exert their therapeutic effects is by normalizing HPA axis hyperactivity in depressedpatients.
Authors: A M Karssen; O C Meijer; I C van der Sandt; P J Lucassen; E C de Lange; A G de Boer; E R de Kloet Journal: Endocrinology Date: 2001-06 Impact factor: 4.736
Authors: P Linkowski; J Mendlewicz; M Kerkhofs; R Leclercq; J Golstein; M Brasseur; G Copinschi; E Van Cauter Journal: J Clin Endocrinol Metab Date: 1987-07 Impact factor: 5.958
Authors: T G Dinan; E Lavelle; J Cooney; F Burnett; L Scott; A Dash; J Thakore; C Berti Journal: Acta Psychiatr Scand Date: 1997-01 Impact factor: 6.392
Authors: R C Veith; N Lewis; J I Langohr; M M Murburg; E A Ashleigh; S Castillo; E R Peskind; M Pascualy; G Bissette; C B Nemeroff Journal: Psychiatry Res Date: 1993-01 Impact factor: 3.222
Authors: Carmine M Pariante; Abdul Hye; Ritchie Williamson; Andrew Makoff; Simon Lovestone; Robert W Kerwin Journal: Neuropsychopharmacology Date: 2003-05-07 Impact factor: 7.853
Authors: Cornelius Schüle; Thomas C Baghai; Daniela Eser; Peter Zwanzger; Martina Jordan; Renate Buechs; Rainer Rupprecht Journal: Psychopharmacology (Berl) Date: 2006-04-22 Impact factor: 4.530
Authors: Livia A Carvalho; Mario F Juruena; Andrew S Papadopoulos; Lucia Poon; Rob Kerwin; Anthony J Cleare; Carmine M Pariante Journal: Neuropsychopharmacology Date: 2008-03-26 Impact factor: 7.853
Authors: Mario F Juruena; Anthony J Cleare; Andrew S Papadopoulos; Lucia Poon; Stafford Lightman; Carmine M Pariante Journal: Psychoneuroendocrinology Date: 2010-06-16 Impact factor: 4.905
Authors: Georg Nikisch; Aleksander A Mathé; Adelheid Czernik; Jutta Thiele; Jürgen Bohner; Chin B Eap; Hans Agren; Pierre Baumann Journal: Psychopharmacology (Berl) Date: 2005-09-29 Impact factor: 4.530
Authors: R Berardelli; E Margarito; F Ghiggia; A Picu; M Balbo; L Bonelli; R Giordano; I Karamouzis; M Bo; E Ghigo; E Arvat Journal: J Endocrinol Invest Date: 2010-04-22 Impact factor: 4.256
Authors: Mario F Juruena; Anthony J Cleare; Andrew S Papadopoulos; Lucia Poon; Stafford Lightman; Carmine M Pariante Journal: Psychopharmacology (Berl) Date: 2006-10-03 Impact factor: 4.530
Authors: Ulla Knorr; Maj Vinberg; Marianne Klose; Ulla Feldt-Rasmussen; Linda Hilsted; Anders Gade; Eva Haastrup; Olaf Paulson; Jørn Wetterslev; Christian Gluud; Ulrik Gether; Lars Kessing Journal: Trials Date: 2009-08-11 Impact factor: 2.279